Original StudyIs Technetium-99m Sestamibi Imaging Able to Predict Pathologic Nonresponse to Neoadjuvant Chemotherapy in Breast Cancer? A Meta-analysis Evaluating Current Use and Shortcomings-Science-Chemical Encyclopedia-lookchem

Original StudyIs Technetium-99m Sestamibi Imaging Able to Predict Pathologic Nonresponse to Neoadjuvant Chemotherapy in Breast Cancer? A Meta-analysis Evaluating Current Use and Shortcomings
Add time:08/22/2019 Source:sciencedirect.com

BackgroundInterest in technetium-99m (99mTc)-sestamibi imaging for neoadjuvant chemotherapy (NAC) response monitoring in locally advanced breast cancer (LABC) is increasing but remains matter of discussion. The present study conducted a meta-analysis of the diagnostic performance of 99mTc-sestamibi to predict pathologic nonresponse to NAC for primary LABC.

We also recommend Trading Suppliers and Manufacturers of TECHNETIUM SESTAMIBI (cas 113720-90-4). Pls Click Website Link as below: cas 113720-90-4 suppliers

Prev:Association for Academic SurgeryTechnetium-99m sestamibi imaging: are the results dependent on the reviewer?
Next: Are Tc-99m-Sestamibi Scans in Patients With Secondary Hyperparathyroidism and Renal Failure Needed?)

Click to view details

Encyclopedia